Pfizer Unveils Monthly GLP-1 Candidate, Lays Out Path to Compete in Obesity Market
Pfizer presented new clinical data and a development plan for berobenatide, a long-acting GLP-1 receptor agonist acquired through Metsera, reporting sustained weight reductions in Phase 2 trials and positioning the drug as a potential once-a-month option as the company scales Phase 3 studies and prepares commercial manufacturing.